|本期目录/Table of Contents|

[1]王 钧,刘 妍,徐东平.隐匿性乙型肝炎病毒感染的研究进展[J].传染病信息,2019,05:390-393+398.
 WANG Jun,LIU Yan*,XU Dong-ping*.Research progress on occult hepatitis B virus infection[J].Infectious Disease Information,2019,05:390-393+398.
点击复制

隐匿性乙型肝炎病毒感染的研究进展(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2019年05期
页码:
390-393+398
栏目:
导向与述评
出版日期:
2019-11-13

文章信息/Info

Title:
Research progress on occult hepatitis B virus infection
文章编号:
1007-8134(2019)05-0390-05
作者:
王 钧刘 妍徐东平
100039,北京大学302临床医学院(王钧);100039北京,中国人民解放军总医院第五医学中心临床研究管理中心/全军传染病研究所(刘妍、徐东平)
Author(s):
WANG Jun LIU Yan* XU Dong-ping*
Peking University 302 Clinical Medical School, 100039, China
关键词:
隐匿性乙型肝炎病毒感染HBV再激活终末期肝病
Keywords:
occult hepatitis B virus infection HBV reactivation end-stage liver disease
分类号:
R512.6
DOI:
10.3969/j.issn.1007-8134.2019.05.002
文献标识码:
A
摘要:
隐匿性乙型肝炎病毒感染( occult HBV infection, OBI)是公共健康的一大难题,也是全球临床医学面临的挑战。由于目前检测方法以及临床实际问题的限制,不同研究中对于 OBI的定义也不同。 OBI的存在会影响临床诊断和输血安全,且 OBI在临床高危人群中有再激活的风险,可能会导致肝硬化、肝癌和肝衰竭等终末期肝病。本文就近年 OBI定义和不同人群流行率、OBI发生机制以及临床意义等研究进展进行综述。
Abstract:
Occult hepatitis B virus infection (OBI) is a great issue for the public health and a challenge for the clinical medicine worldwide. Several definitions of OBI have been described in different researches due to present limited testing methods and clinicalpractice. OBI may affect the diagnosis and blood transfusion safety, and OBI reactivation is a main risk factor for clinical high-riskpatients. In addition, OBI may result in end-stage liver diseases such as liver cirrhosis, hepatocellular carcinoma and liver hepaticfailure. This paper reviews the definition, prevalence, mechanism and clinical implications of OBI based on recent researches.

参考文献/References

[1] Chen BF. Hepatitis B virus pre-S/S variants in liver diseases[J]. World J Gastroenterol, 2018, 24(14):1507-1520.
[2] Makvandi M. Update on occult hepatitis B virus infection[J]. World J Gastroenterol, 2016, 22(39):8720-8734.
[3] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1):1-98.
[4] Kwak MS, Kim YJ. Occult hepatitis B virus infection[J]. World J Hepatol, 2014, 6(12):860-869.
[5] Liu Y, Zeng W, Xi J, et al. Over-gap PCR amplification to identify presence of replication- competent HBV DNA from integratedHBV DNA: an updated occult HBV infection definition[J].J Hepatol, 2019, 70(3):557-559.
[6] Su H, Shao Z, Pu Z, et al. Overt and occult hepatitis B virusinfection among community children in Northwest China[J].J Viral Hepat, 2017, 24(9):797-803.
[7] Huang CH, Yuan Q, Chen PJ, et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotypein occult HBV strains from blood donors[J]. J Hepatol, 2012, 57(4):720-729.
[8] Malagnino V, Fofana DB, Lacombe K, et al. Occult hepatitis Bvirus infection: an old entity with novel clinical involvements[J]. Open Forum Infect Dis, 2018, 5(10):ofy227.
[9] Liao H, Liu Y, Chen JH, et al. Characterization of hepatitis B virus (HBV) preS/S gene mutations in blood donors with occult HBVinfection in the Baoji area of North China[J]. Transfusion, 2017, 57(3):857-866.
[10] 张凯,徐东平,陈容娟,等 . 临床大样本肝病患者隐匿性 HBV感染检出情况及其 HBV S基因免疫逃逸突变特点分析[J]. 解放军医学杂志,2018,43(5):380-385.
[11] 卢姗姗,徐东平,李进,等 . HBV前 S/S基因突变的研究进展[J]. 传染病信息,2016,29(2):112-116.
[12] Pollicino T, Raffa G, Costantino L, et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients withhepatocellular carcinoma[J]. Hepatology, 2007, 45(2):277-285.
[13] Zhu HL, Li X, Li J, et al. Genetic variation of occult hepatitis B virus infection[J]. World J Gastroenterol, 2016, 22(13):3531?3546.
[14] Ponde RA. Molecular mechanisms underlying HBsAg negativity in occult HBV infection[J]. Eur J Clin Microbiol Infect Dis, 2015, 34(9):1709-1731.
[15] Zhang K, Liu Y, Chen RJ, et al. Antigenicity reduction contributes mostly to poor detectability of HBsAg by hepatitis B virus (HBV)S-gene mutants isolated from individuals with occult HBV infection[J]. J Med Virol, 2018, 90(2):263-270.
[16] 刘妍,张凯,陈容娟,等 . 隐匿性 HBV感染患者 HBV S基因 N-糖基化突变对 HBsAg抗原性影响的分析[J]. 解放军医学杂志, 2018,43(5):386-391.
[17] Chen YY, Li LM, Zhou ZX, et al. A pilot study of serum microRNA signatures as a novel biomarker for occult hepatitis B virus infection[J]. Med Microbiol Immunol, 2012, 201(3):389-395.
[18] Esposito A, Sabia C, Iannone C, et al. Occult hepatitis infection in transfusion medicine: screening policy and assessment of currentuse of anti-HBc testing[J]. Transfus Med Hemother, 2017, 44(4):263-272.
[19] Spreafico M, Berzuini A, Foglieni B, et al. Poor efficacy of nucleic acid testing in identifying occult HBV infection and consequences for safety of blood supply in Italy[J]. J Hepatol, 2015, 63(5):1068-1076.
[20] Allain JP, Mihaljevic I, Gonzalez-Fraile MI, et al. Infectivity ofblood products from donors with occult hepatitis B virus infection[J]. Transfusion, 2013, 53(7):1405-1415.
[21] 黄象艳,石庆芬,黄涛,等 . 隐匿性乙型肝炎病毒感染研究进展[J]. 中华流行病学杂志,2017,38(5):688-692.
[22] Lu Y, Liu YL, Nie JJ, et al. Occult HBV infection in immunized neonates born to HBsAg-positive mothers: a prospective andfollow-up study[J]. PLoS One, 2016, 11(11):e0166317.
[23] Hashemi SJ, Hajiani E, Masjedizadeh A, et al. Occult Hepatitis B infection in patients with cryptogenic liver cirrhosis in southwest of Iran[J]. Jundishapur J Microbiol, 2015, 8(3):e16873.
[24] Germanidis G, Hytiroglou P, Zakalka M, et al. Reactivation of occult hepatitis B virus infection, following treatment of refractoryrheumatoid arthritis with abatacept[J]. J Hepatol, 2012, 56(6):1420-1421.
[25] Martin CM, Welge JA, Shire NJ, et al. Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals[J]. Cytokine, 2009, 47(3):194-198.
[26] Chen JH, Liu Y, Zhao J, et al. Characterization of novel hepatitisB virus PreS/S-gene mutations in a patient with occult hepatitis B virus infection[J]. PLoS One, 2016, 11(5):e0155654.
[27] 李奇,张凯,思兰兰,等 . 隐匿性乙型肝炎病毒(HBV)感染患者 HBV S基因突变特点及突变病毒株致瘤性研究[J]. 传染病信息,2019,32(3): 208-214.
[28] Lledo JL, Fernandez C, Gutierrez ML, et al. Management of occult hepatitis B virus infection: an update for the clinician[J]. World J Gastroenterol, 2011, 17(12):1563-1568.
[29] Chen GF, Wang C, Chen J, et al. Hepatitis B reactivation inhepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis[J]. Hepatology, 2017, 66(1):13-26.
[30] Vigano M, Aghemo A, Iavarone M, et al. The course of inactive hepatitis B in hepatitis-C-coinfected patients treated withinterferon and ribavirin[J]. Antivir Ther, 2009, 14(6):789-796.
[31] Chuang WL, Dai CY, Chang WY, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients withinterferon-alpha plus ribavirin combination therapy[J]. Antivir Ther, 2005, 10(1):125-133.
[32] De Monte A, Courjon J, Anty R, et al. Direct-acting antiviraltreatment in adults infected with hepatitis C virus: reactivation ofhepatitis B virus coinfection as a further challenge[J]. J Clin Virol, 2016, 78:27-30.
[33] Hayashi K, Ishigami M, Ishizu Y, et al. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevircombination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?[J]. Clin J Gastroenterol, 2016, 9(4):252-256.
[34] Takayama H, Sato T, Ikeda F, et al. Reactivation of hepatitis B virusduring interferon-free therapy with daclatasvir and asunaprevir inpatient with hepatitis B virus/hepatitis C virus co-infection[J]. Hepatol Res, 2016, 46(5):489-491.
[35] Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation ofhepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents[J]. Clin Gastroenterol Hepatol, 2017, 15(1):132-136.
[36] Xie M, Rao W, Yang T, et al. Occult hepatitis B virus infectionpredicts de novo hepatitis B infection in patients with alcoholiccirrhosis after liver transplantation[J]. Liver Int, 2015, 35(3):897-904.
[37] Ye XL, Li T, Xu XX, et al. Characterisation and follow-up studyof occult hepatitis B virus infection in anti-HBc-positive qualified blood donors in southern China[J]. Blood Transfus, 2017, 15(1):6-12.
[38] Tandoi F, Caviglia GP, Pittaluga F, et al. Prediction of occult hepatitis B virus infection in liver transplant donors throughhepatitis B virus blood markers[J]. Dig Liver Dis, 2014, 46(11):1020-1024.
[39] Caviglia GP, Abate ML, Tandoi F, et al. Quantitation of HBVcccDNA in anti-HBc-positive liver donors by droplet digitalPCR: a new tool to detect occult infection[J]. J Hepatol, 2018, 69(2):301-307.
[40] Sagnelli E, Pisaturo M, Martini S, et al. Clinical impact of occulthepatitis B virus infection in immunosuppressed patients[J]. World J Hepatol, 2014, 6(6):384-393.
[41] Sugauchi F, Tanaka Y, Kusumoto S, et al. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy[J]. J Med Virol, 2011, 83(3):412?418.
[42] Coppola N, Tonziello G, Pisaturo M, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings[J]. J Med Virol, 2011, 83(11):1909-1916.
[43] Elkady A, Aboulfotuh S, Ali EM, et al. Incidence and characteristics of HBV reactivation in hematological malignantpatients in south Egypt[J]. World J Gastroenterol, 2013, 19(37):6214-6220.

备注/Memo

备注/Memo:
[基金项目]国家自然科学基金(81572010);首都卫生发展科研专项项目(2016-2-5032);北京市自然科学基金(7172206)
[作者单位]100039,北京大学302临床医学院(王钧);100039北京,中国人民解放军总医院第五医学中心临床研究管理中心/全军传染病研究所(刘妍、徐东平)
[通信作者]徐东平,E-mail:xudongping302@sina.com;刘妍,E-mail:liuyan5360@163.com
*Correspondingauthor.XUDong-ping,E-mail:xudongping302@sina.com;LIUYan,E-mail:liuyan5360@163.com
更新日期/Last Update: 2019-11-13